Designing drug trials for Alzheimer's disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force

B. Vellas, M.C. Carrillo, C. Sampaio, H.R. Brashear, E. Siemers, H. Hampel, L.S. Schneider, M. Weiner, R. Doody, Z. Khachaturian, J. Cedarbaum, M. Grundman, K. Broich, E. Giacobini, B Dubois, R. Sperling, G.K. Wilcock, N.C. Fox, P. Scheltens, J. TouchonS. Hendrix, S. Andrieu, P. Aisen

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)438-444
JournalAlzheimers & Dementia
Volume9
Issue number4
DOIs
Publication statusPublished - 2013

Cite this